These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1324 related articles for article (PubMed ID: 31511088)

  • 41. Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice.
    Ito H; Ando T; Ogiso H; Arioka Y; Seishima M
    Cancer Immunol Immunother; 2015 Apr; 64(4):429-36. PubMed ID: 25567751
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Delivery of TLR7 agonist to monocytes and dendritic cells by DCIR targeted liposomes induces robust production of anti-cancer cytokines.
    Klauber TCB; Laursen JM; Zucker D; Brix S; Jensen SS; Andresen TL
    Acta Biomater; 2017 Apr; 53():367-377. PubMed ID: 28153581
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells.
    Smits EL; Cools N; Lion E; Van Camp K; Ponsaerts P; Berneman ZN; Van Tendeloo VF
    Cancer Immunol Immunother; 2010 Jan; 59(1):35-46. PubMed ID: 19449004
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma.
    Cho JH; Lee HJ; Ko HJ; Yoon BI; Choe J; Kim KC; Hahn TW; Han JA; Choi SS; Jung YM; Lee KH; Lee YS; Jung YJ
    Oncotarget; 2017 Apr; 8(15):24932-24948. PubMed ID: 28212561
    [TBL] [Abstract][Full Text] [Related]  

  • 45. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.
    Johnson TR; Rao S; Seder RA; Chen M; Graham BS
    Vaccine; 2009 May; 27(23):3045-52. PubMed ID: 19428918
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
    Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
    Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
    Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
    Front Immunol; 2022; 13():794684. PubMed ID: 35720386
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists.
    Triozzi PL; Aldrich W; Ponnazhagan S
    Vaccine; 2010 Nov; 28(50):7837-43. PubMed ID: 20937315
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8.
    Wang D; Precopio M; Lan T; Yu D; Tang JX; Kandimalla ER; Agrawal S
    Mol Cancer Ther; 2010 Jun; 9(6):1788-97. PubMed ID: 20515950
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activation of innate immunity in primary human cells using a plant virus derived nanoparticle TLR7/8 agonist.
    Carignan D; Herblot S; Laliberté-Gagné MÈ; Bolduc M; Duval M; Savard P; Leclerc D
    Nanomedicine; 2018 Oct; 14(7):2317-2327. PubMed ID: 29128662
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Imiquimod enhances the potency of an exogenous BM-DC based vaccine against mouse melanoma.
    Ren S; Wang Q; Zhang Y; Song Y; Dong X; Zhang W; Qin X; Liu M; Yu T
    Int Immunopharmacol; 2018 Nov; 64():69-77. PubMed ID: 30149266
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
    Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
    Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
    J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.
    Reilley MJ; Morrow B; Ager CR; Liu A; Hong DS; Curran MA
    J Immunother Cancer; 2019 Nov; 7(1):323. PubMed ID: 31771649
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist.
    Hosoya T; Sato-Kaneko F; Ahmadi A; Yao S; Lao F; Kitaura K; Matsutani T; Carson DA; Hayashi T
    Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6836-E6844. PubMed ID: 29967183
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Accessory-cell-mediated activation of porcine NK cells by toll-like receptor 7 (TLR7) and TLR8 agonists.
    Toka FN; Nfon CK; Dawson H; Golde WT
    Clin Vaccine Immunol; 2009 Jun; 16(6):866-78. PubMed ID: 19369481
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Large, Anionic Liposomes Enable Targeted Intraperitoneal Delivery of a TLR 7/8 Agonist To Repolarize Ovarian Tumors' Microenvironment.
    Kang Y; Flores L; Ngai HW; Cornejo YR; Haber T; McDonald M; Moreira DF; Gonzaga JM; Abidi W; Zhang Y; Hammad M; Kortylewski M; Aboody KS; Berlin JM
    Bioconjug Chem; 2021 Aug; 32(8):1581-1592. PubMed ID: 34289694
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A chemical conjugation of JQ-1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation.
    Wang X; Yu B; Cao B; Zhou J; Deng Y; Wang Z; Jin G
    Int J Cancer; 2021 Jan; 148(2):437-447. PubMed ID: 32683685
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antitumor activity of a novel small molecule TLR7 agonist via immune response induction and tumor microenvironment modulation.
    Diao Y; Wang X; Wan Y; Zhong J; Gao D; Liu Y; Gao N; Li W; Liu B; Huang X; Jin Z; Peng B; Wang Z; Fu L; Chen S; Jin G
    Oncol Rep; 2016 Feb; 35(2):793-800. PubMed ID: 26718332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.